Last edition
News about "Acquisition of Bluejay"
High-Impact HDV Candidate Drives Mirum's 620 Million USD Acquisition of Bluejay
Mirum Pharmaceuticals, Inc., a leading rare disease company, has entered a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology firm focused on viral and liver diseases.
Acquisition Of Bluejay | 09/12/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members